Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2041 to 2055 of 8933 results

  1. Artificial Intelligence (AI)-assisted echocardiography analysis and reporting to support the diagnosis and monitoring of heart failure: Early Value Assessment: draft guidance

    We are listening to your views on this Health technology evaluation. Comments close 24 February 2026.

  2. Bladder EpiCheck for the detection of bladder cancer recurrence (MT706)

    Topic prioritisation

  3. Polihexanide 0.8 mg/ml eye drops for treating acanthamoeba keratitis in people 12 years and over [ID6497]: draft guidance

    We are listening to your views on this Technology appraisal guidance. Comments close 6 March 2026.

  4. SEEG-guided radiofrequency thermocoagulation in refractory epilepsy

    Topic prioritisation

  5. Lumella Pre-Eclampsia Test (MT687)

    Topic prioritisation

  6. Ciclosporin (Vevizye) eye drops for treating moderate to severe keratoconjunctivitis [TSID12293]

    Topic prioritisation

  7. Dronabinol for treating muscle spasticity in multiple sclerosis after 2 treatments [TSID10638]

    Topic prioritisation

  8. Anitocabtagene autoleucel for treating relapsed or refractory multiple myeloma [ID6549]

    Topic prioritisation

  9. Tirzepatide for treating type 2 diabetes [ID3938]: review proposal consultation

    We are listening to your views on this Technology appraisal guidance. Comments close 18 March 2026.

  10. Neonatal infection: antibiotics for prevention and treatment - update: draft guidance consultation

    We are listening to your views on this NICE guideline. Comments close 4 March 2026.

  11. Heart failure - sacubitril valsartan [ID822]: review proposal consultation

    We are listening to your views on this Technology appraisal guidance. Comments close 18 March 2026.

  12. Empagliflozin for treating chronic heart failure with reduced ejection fraction [ID3826]: review proposal consultation

    We are listening to your views on this Technology appraisal guidance. Comments close 18 March 2026.

  13. Empagliflozin in combination therapy for treating type 2 diabetes: review proposal consultation

    We are listening to your views on this Technology appraisal guidance. Comments close 18 March 2026.

  14. Ertugliflozin in a triple therapy regimen for treating type 2 diabetes [ID1160]: review proposal consultation

    We are listening to your views on this Technology appraisal guidance. Comments close 18 March 2026.

  15. Ertugliflozin as monotherapy and in dual therapy for treating type 2 diabetes [ID1158]: review proposal consultation

    We are listening to your views on this Technology appraisal guidance. Comments close 18 March 2026.